# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-22-036613
Filing Date
2022-11-03
Accepted
2022-11-03 16:15:44
Documents
6
Period of Report
2022-12-15

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | abio-def14a_20221215.htm | DEF 14A | 733131
2 | GRAPHIC | gwk2ytx2g3li000004.jpg | GRAPHIC | 983559
3 | GRAPHIC | gwk2ytx2g3li000002.jpg | GRAPHIC | 37943
4 | GRAPHIC | gwk2ytx2g3li000005.jpg | GRAPHIC | 269565
5 | GRAPHIC | gwk2ytx2g3li000003.jpg | GRAPHIC | 37943
6 | GRAPHIC | gwk2ytx2g3li000001.jpg | GRAPHIC | 37943
| Complete submission text file | 0001564590-22-036613.txt |  | 2617573

Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-22873 | Film No.: 221358214
SIC: 2835 In Vitro & In Vivo Diagnostic Substances